Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

NCT00652496 Phase 2 COMPLETED

This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension. One of the test formulations was given to one eye and bimatoprost 0.03% given to the fellow eye of each patient

Details

Lead sponsor	Allergan
Phase	Phase 2
Status	COMPLETED
Enrolment	249
Start date	2005-01
Completion	2005-05

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

• Bimatoprost 0.01% ophthalmic solution
• Bimatoprost 0.015% formulation 1 ophthalmic solution
• Bimatoprost 0.015% formulation 2 ophthalmic solution
• Bimatoprost 0.02% ophthalmic solution
• Bimatoprost 0.03% ophthalmic solution

Primary outcomes

• Intraocular pressure (IOP) — Day 5

Countries

United States